Send to

Choose Destination
Diabetes Obes Metab. 2012 Jul;14(7):596-600. doi: 10.1111/j.1463-1326.2012.01567.x. Epub 2012 Feb 20.

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.

Author information

Clinical Innovations, Medco Health Solutions, Franklin Lakes, New Jersey, USA.



This study evaluated whether the risk of acute renal failure (ARF) increases with exenatide and sitagliptin use.


A retrospective cohort study of a large medical and pharmacy claims database was performed. Data for 4 91 539 patients were analysed. Cox proportional hazard models were used to compare the risk of ARF between diabetic and non-diabetic subjects and between diabetic patients treated with exenatide, sitagliptin and control medications.


Adjusted Cox analyses showed diabetic subjects had a higher risk of ARF [HR 1.51, confidence interval (CI) 1.26-1.81, p < 0.001] than non-diabetic controls. Compared with diabetic controls, neither exenatide (HR 0.77, CI 0.42-1.41, p = 0.40) nor sitagliptin (HR 1.17, CI 0.82-1.65, p = 0.39) increased the risk of ARF.


Our study revealed an increased incidence of ARF in diabetic versus non-diabetic patients but no association between use of exenatide or sitagliptin and ARF. Because of the limitations of this observational analysis, we cannot exclude the possibility of a very small increased risk.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center